Emend Tri-Pack · DIN 02298813 · 125 mg & 80 mg · capsule
Limited Use, Reason for Use code 452, 453 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 452, 453 required
Write on scriptone applicable Reason for Use code, 452 or 453 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Ontario Limited Use criteria, code 452, 453
Reason for Use code 452
In combination with a 5HT3 receptor antagonist and dexamethasone for highly emetogenic chemotherapy (HEC) regimens:
- Cisplatin-based chemotherapy where a single daily dose is greater than or equal to 70 mg per meter squared
- Cisplatin and cyclophosphamide combinations where the single daily dose is greater than or equal to 50mg per meter squared
- Cisplatin (any dose) given for 3 to 5 consecutive days
- Non-cisplatin based highly emetogenic chemotherapy (such as those containing anthracycline greater than or equal to 60mg per meter squared plus cyclophosphamide)
Dosage: Recommend aprepitant 125mg orally on Day 1 of HEC followed by 80mg orally on Days 2 to 3 post-chemotherapy for each cycle.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 453
For patients receiving moderately emetogenic chemotherapy (MEC) regimens AND who have had inadequate symptom control using a 5HT3 antagonist and dexamethasone in a previous cycle.
Dosage: Recommend aprepitant 125mg orally on Day 1 of MEC followed by 80mg orally on Days 2 to 3 post-chemotherapy for each cycle.
Coverage limit:
LU Authorization Period: 1 year
Exceptional Access criteria on record are for Brand(s): Emend; DOSAGE FORM/ STRENGTH: 80 mg,125 mg capsule,Tri-pack — not this product; no criteria on record for this product in this block.
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Aprepitant
Brand(s): Emend
DOSAGE FORM/ STRENGTH: 80 mg,125 mg capsule,Tri-pack
Effective September 25, 2014, Emend transitioned to the ODB formulary for
reimbursement in patients who meet the Limited Use criteria. Dosage regimens not
meeting the LU criteria may be submitted to the EAP for consideration of reimbursement.
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 392, record 224, corpus 2025-01-01; name match only, not an eligibility decision
No interchangeable product listed in the Ontario extract
Emend Tri-Pack · DIN 02298813
Manufacturer: Merck Canada Inc.; listing date 2014-09-25
Health Canada: Marketed since 2007-09-24 · brand EMEND TRI-PACK · ATC A04AD12 APREPITANT · form Capsule, Kit · route Oral · ingredients APREPITANT 125 MG, APREPITANT 80 MG · company Merck canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordEmend Tri-Pack: Formulary list price $106.98 per unit (the source does not state the unit; exact figure $106.9839). What the ministry pays, not the patient.
Ministry pays: $106.9839 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02298813)
Source record
DIN 02298813: Emend Tri-Pack
Raw flags: sec12=Y, sec3=Y
Item: 562200043; group id 662; item number 1650; lccId 00243; manufacturer id MEK
Source form: Cap; strength: 125mg & 80mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $106.9839; ministry $106.9839
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02298813
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78412
Shortage status: To be discontinued · Tier 3; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02298813
Shortage record checked October 6, 2026